Atlas Trials

Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia

Clinical trial NCT05429905 · UNKNOWN

Trial details

NCT number
NCT05429905
Sponsor
KK Women's and Children's Hospital
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Lymphoblastic LeukemiaLymphoblastic Leukemia, Acute, ChildhoodLymphoblastic Leukemia in ChildrenLymphoblastic Leukemia, Acute AdultCAR
Start date
2022-07-18
Primary completion
2024-12-01
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.